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Introduction {#sec1}
============

B cells are key components of adaptive immunity that provide systemic defense against pathogenic infections through the production of highly specific antibodies. Antibody-secreting plasma cell generation depends on B cell activation, in which naive B cells are instructed to undergo cycles of proliferation and differentiation. The first signal required for B cell activation is initiated upon specific engagement of the B cell receptor (BCR) by its cognate antigen (Ag), resulting in a complex signaling cascade and uptake of the BCR:Ag complex. The internalized antigen is presented as cell surface peptides on class II major histocompatibility complex molecules (MHC-II) ([@bib2]), resulting in the engagement of specific CD4^+^ helper T cells and thus providing a second signal for maximal B cell activation. *In vivo*, activated B cells can rapidly differentiate to antibody-secreting plasma cells or enter into germinal centers (GCs) where BCR affinity maturation and class switch recombination take place ([@bib35], [@bib27], [@bib10], [@bib47]). B cells in the GC shuttle between the light and the dark zone and BCRs with high antigen affinity are iteratively selected. These B cells exit the GC and differentiate into either high-affinity antibody secreting long-lived plasma cells or temporarily quiescent memory cells that can undergo plasma cell differentiation upon re-encountering the same antigen ([@bib27]).

Previous efforts have established transcriptomic signatures that distinguish the changes of identity to predict B cell fate decision. For example, the high expression of the transcription factors BLIMP-1 (*Prdm1*) ([@bib33], [@bib40]) and IRF4 ([@bib19], [@bib39]) are reliable hallmarks of plasma cells (effector) development, while the expression of the transcription repressor BACH2 ([@bib20], [@bib41]) can predict memory progression. However, the signaling network and regulatory mechanisms required for B cell fate decisions are not fully understood. Recent data suggest that metabolic reprogramming during lymphocyte activation is, in part, important for regulating fate decisions in T cells ([@bib34], [@bib46], [@bib51]).

Protein kinase Cs (PKCs) are signaling molecules that play key roles in many cellular processes. The PKC family is broadly divided into three subgroups: classical, novel, and atypical PKCs ([@bib28]). These subgroups differ in both protein sequences and mechanistic requirements for catalytic activity. The classical PKCs require cytosolic calcium (Ca^2+^) for their activity, while the novel and atypical PKCs do not ([@bib28]). In B cells, PKCβ is the most highly expressed PKC member and plays a central part in propagating NF-κB signaling and cell proliferation downstream of the BCR ([@bib38], [@bib44]). PKCβ-null mice exhibit impaired B cell development in the peritoneal cavity ([@bib23]) and (more mildly) the spleen ([@bib23]) and diminished humoral responses against T cell-dependent antigen ([@bib23]).

Here we reveal that PKCβ is essential for the regulation of antigen polarization and cell-fate decision in activated B cells. Using mice whose B cells lack PKCβ, we show that this protein is essential for GCs and plasma cell development upon immunization. Indeed, PKCβ-deficient B cells exhibit impaired antigen polarization and presentation that is likely to hinder GC development. Additionally, PKCβ promotes mTORC1-dependent mitochondrial remodeling and heme biosynthesis, resulting in BLIMP1-driven plasma cell differentiation ([@bib50]). Thus, our study provides mechanistic insights into the key role of PKCβ on B cell-fate decisions.

Results {#sec2}
=======

PKCβ Promotes Germinal Center Formation and Plasma Cell Differentiation {#sec2.1}
-----------------------------------------------------------------------

While *Prkcb*^−/−^ mice exhibit severe immunodeficiency in response to T cell-dependent antigens ([@bib23]), it is unclear whether B cells contribute to the severe phenotype in these mice. To investigate whether the loss of PKCβ in B cells attenuates immune response *in vivo*, we initially generated mixed bone marrow (BM) chimeras whereby irradiated μMT mice (mature B cell-deficient) were reconstituted with a mixture of 80% μMT BM and either 20% WT (WT chimeras) or 20% *Prkcb*^−/−^ (*Prkcb*^−/−^ chimeras) BM. Thus, reconstituted *Prkcb*^−/−^ chimeras would harbor *Prkcb*^−/−^ B cells in an environment of mostly WT cells. The degree of reconstitution was assessed 6 to 8 weeks after adoptive transfer ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We then challenged WT and *Prkcb*^−/−^ chimeras with NP~23~ conjugated to keyhole limpet haemocyanin (KLH) and Alum via intra-peritoneal injection and analyzed the immune response in the spleen at day 13 ([Figures 1](#fig1){ref-type="fig"}A--1G). In WT chimeras, we observed robust GC B cell development, indicated by the increased B220^+^GL7^+^CD95^+^ population ([Figure 1](#fig1){ref-type="fig"}A). In contrast, we saw a severe reduction in the GC B cell population in *Prkcb*^−/−^ chimeras ([Figure 1](#fig1){ref-type="fig"}A). By inspecting splenic sections using confocal microscopy, we observed that both the quantity and area of GC significantly decreased in immunized *Prkcb*^−/−^ chimeras ([Figures 1](#fig1){ref-type="fig"}B). Our data suggest that PKCβ in B cells plays an important role in promoting GC reaction.Figure 1PKCβ Promotes Robust B Cell Response *In Vivo*(A) Splenic GC B cell populations (B220^+^NP^+^GL7^+^CD95^+^) as analyzed by flow cytometry 13 days after NP-KLH and alum immunization of WT or *Prkcb*^−/−^ chimeras.(B) Confocal (20× objectives) tile images of the spleen of immunized WT and *Prkcb*^−/−^ mice showing B220 and GL7 staining. Scale bar, 700 μm. The quantity and area of GCs were quantified using Imaris.(C) Splenic Tfh cells (CD4^+^PD1^+^CXCR5^+^) were quantified 13 days after immunization.(D) NP-specific IgG and IgM titers on the specified days were determined by ELISA.(E) Splenic plasma cells (CD138^+^IgD^−^) were quantified 13 days after immunization.(F) Confocal (20× objectives) tile images of the spleen of immunized WT and *Prkcb*^−/−^ mice showing surface B220 and intracellular κ staining. Scale bar, 700 μm. The amount of intracellular-κ^+^ cells were quantified using Imaris.(G) NP-specific IgG- and IgM-secreting cells 13 days after immunization were quantified by ELISPOT.(H) Plasma cells (CD138^+^IgD^−^) in the PLN of WT or *Prkcb*^−/−^ chimeras were quantified 7 days after vaccinia infection using flow cytometry.(I) PLN VACV-specific IgM-secreting cells 7 days after infection were quantified using ELISPOT. All data are representative of at least 2 independent experiments. Each dot represents one mouse.Error bars represent SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

We asked whether this was an intrinsic feature in *Prkcb*^−/−^ B cells and so we tested the ability of *Prkcb*^−/−^ B cells to differentiate to GC-like B cells *in vitro*. We cultured primary WT and *Prkcb*^−/−^ B cells with 40LB cells ([@bib32]) for 4 days and measured GL7 and CD95 expression using flow cytometry. We detected more than 80% of WT and *Prkcb*^−/−^ B cells exhibiting GC-like features by day 4 ([Figure S1](#mmc1){ref-type="supplementary-material"}B), suggesting that *Prkcb*^−/−^ B cells were capable of forming GC B cells.

The formation of GCs *in vivo* depends on follicular T helper (Tfh) cells, as they provide essential co-stimulatory signals to B cells ([@bib48]). We therefore compared the development of Tfh cells in WT and *Prkcb*^−/−^ chimeras 13 days after immunization. We detected a robust induction of Tfh cells (CD4^+^CXCR5^+^PD1^+^) in WT chimeras ([Figure 1](#fig1){ref-type="fig"}C). In contrast, Tfh cell development in immunized *Prkcb*^−/−^ chimeras was reduced compared to immunized WT chimeras ([Figure 1](#fig1){ref-type="fig"}C), indicating that the absence of PKCβ in B cells affected the development of Tfh cells.

Robust GC reaction facilitates the production of class-switched antibodies and affinity maturation. In line with a defective GC response ([Figures 1](#fig1){ref-type="fig"}A and 1B), *Prkcb*^−/−^ chimeras showed delayed and diminished appearance of NP~23~-specific IgG titer as compared to WT chimeras ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}C), suggesting that the production of class-switched antibodies was affected by the loss of PKCβ. Moreover, we found that the IgG derived from *Prkcb*^−/−^ chimeras bound poorly to NP~3~ ([Figure 1](#fig1){ref-type="fig"}D), reflecting a lack of high-affinity IgG in immunized *Prkcb*^−/−^ chimeras. These data demonstrate that antibody class-switching and affinity maturation was affected in immunized *Prkcb*^−/−^ chimeras.

Notably, we found that IgM production was completely abrogated in immunized *Prkcb*^−/−^ chimeras ([Figure 1](#fig1){ref-type="fig"}D). As primary IgM titer is typically derived from extrafollicular plasma cells, which are independent of the GC, we asked whether plasma cell development was affected in the absence of PKCβ. We analyzed plasma cell differentiation in immunized WT and *Prkcb*^−/−^ chimeras, and found that while WT chimeras exhibited a 5-fold increase of splenic plasma cells (CD138^+^IgD^−^) after immunization, no induction of plasma cell differentiation could be detected in the *Prkcb*^−/−^ chimeras ([Figure 1](#fig1){ref-type="fig"}E). When inspecting splenic sections by confocal microscopy, we observed a marked reduction of plasma cells in the splenic extrafollicular area in *Prkcb*^−/−^ chimeras versus WT chimeras ([Figure 1](#fig1){ref-type="fig"}F). These results were confirmed by ELISPOT analysis ([Figure 1](#fig1){ref-type="fig"}G). Taken together, our findings suggest that PKCβ plays an important role not only in promoting GC response but also in the generation of extrafollicular plasma cells.

To determine whether the loss of PKCβ in B cells would also affect plasma cell differentiation in the context of viral infection, we challenged WT and *Prkcb*^−/−^ chimeras, intra-footpad, with 10^4^ PFU of vaccinia virus and analyzed plasma cell differentiation in the draining popliteal lymph nodes (PLNs) 7 days after infection. We observed robust CD138^+^IgD^−^ plasma cells formation in the PLNs of WT chimeras; in contrast, the development of these cells was reduced in the PLNs of infected *Prkcb*^−/−^ chimeras ([Figure 1](#fig1){ref-type="fig"}H). Furthermore, ELISPOT analysis also revealed a reduction in the amount of VACV-specific IgM-secreting cells in the PLNs of infected *Prkcb*^−/−^ chimeras compared to WT chimeras ([Figure 1](#fig1){ref-type="fig"}I). Together, these results suggest an important role for PKCβ in plasma cell differentiation *in vivo*.

Antigen Polarization in B Cells Requires PKCβ {#sec2.2}
---------------------------------------------

Subsequently, we questioned how the loss of PKCβ affects B cell functions at the cellular level. BCR engagement results in a rapid internalization of the BCR:Ag complex and the polarization of antigen-containing compartments ([Figure S2](#mmc1){ref-type="supplementary-material"}A), which was suggested to be dependent on classical PKCs ([@bib42]). We therefore asked whether PKCβ is specifically required for antigen polarization in B cells. We stimulated primary WT, *Prkca*^−/−^, and *Prkcb*^−/−^ B cells for 30 min with Alexa647-conjugated anti-IgM and compared antigen polarization using confocal microscopy ([Figures 2](#fig2){ref-type="fig"}A and 2B). While about 60% of WT B cells and 50% of *Prkca*^−/−^ B cells displayed polarized antigen ([Figures 2](#fig2){ref-type="fig"}A and 2B), it was reduced to 30% in *Prkcb*^−/−^ B cells ([Figure 2](#fig2){ref-type="fig"}B). This result indicates that PKCβ is required for intracellular antigen polarization but not antigen internalization (see [STAR Methods](#sec4){ref-type="sec"}; [Figure S2](#mmc1){ref-type="supplementary-material"}B).Figure 2PKCβ Facilitates Intracellular Antigen Trafficking in B Cells(A) Confocal images (63× objectives) of primary WT, *Prkca*^−/−^, and *Prkcb*^−/−^ B cells stimulated with Alexa647-conjugated anti-IgM for 30 min. Magenta dots indicate the corresponding MTOC. Bars, 5 μm.(B) The extent of antigen polarization was quantified using ImageJ. Data were analyzed using two-way ANOVA.(C) Representative plots of surface MHC-II:Eα expression as detected by anti-MHC-II:Eα antibody. Data are representative of at least 2 independent experiments.(D) MFI of MHC-II:Eα was quantified. Data were analyzed using two-way ANOVA and are representative of 3 independent experiments.(E) Primary WT and *Prkcb*^−/−^ B cells incubated with anti-IgM and OVA-coated beads and co-cultured with OT-II T cells. Representative plots showing CFSE and CTV dilutions on day 3. Data are representative of at least 2 independent experiments.(F) Quantification of CTV-divisions of WT and *Prkcb*^−/−^ B cells in the co-culture experiment.(G and H) Representative plots and quantification of cell recovery of WT and *Prkcb*^−/−^ B cells after 3 days of co-culture.(I) Representative plots of CTV dilutions of WT and *Prkcb*^−/−^ B cells stimulated with CD40L, anti-IgM, and IL-4 for 3 days.(J and K) Representative plots of CTV dilutions of WT, *Prkca*^−/−^, and *Prkcb*^−/−^ B cells stimulated with (J) anti-IgM and CpG-coated microspheres with IL-4 and IL-5, or (K) anti-IgM, CpG, IL-4, and IL-5 for 3 days. Data are representative of at least 2 independent experiments.Error bars represent SEM. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Antigen polarization is thought to facilitate efficient antigen transfer to MHC-II molecules, required for the subsequent presentation to T cells ([@bib42]); therefore, we examined whether *Prkcb*^−/−^ B cells were less capable of antigen presentation (see [STAR Methods](#sec4){ref-type="sec"}). Accordingly, we stimulated primary WT, *Prkca*^−/−^, and *Prkcb*^−/−^ B cells with anti-IgM and Eα peptide-coated microspheres. The internalized Eα peptide is transferred to MHC-II (I-A^b^) and presented on the cell surface ([@bib36]), which we detected using an anti-MHC-II:Eα antibody ([Figure 2](#fig2){ref-type="fig"}C). In WT and *Prkca*^−/−^ B cells, we observed robust Eα-presentation corresponding to a 3-fold increase in mean fluorescence intensity (MFI) by the end time point ([Figures 2](#fig2){ref-type="fig"}C and 2D). However, the MFI was decreased by 50% in *Prkcb*^−/−^ B cells ([Figures 2](#fig2){ref-type="fig"}C and 2D), indicating that antigen presentation was impaired in *Prkcb*^−/−^ but not *Prkca*^−/−^ B cells. To assess how this might influence presentation to T cells, we assayed the response of WT and *Prkcb*^−/−^ B cells in co-culture with OT-II CD4^+^ T cells (see [STAR Methods](#sec4){ref-type="sec"}). CellTrace Violet (CTV)-labeled WT and *Prkcb*^−/−^ B cells were stimulated with anti-IgM and OVA-coated microspheres and co-cultured with CFSE-labeled OT-II T cells. After 3 days, we assessed the proliferation of B and T cells using flow cytometry. WT and *Prkcb*^−/−^ B cells triggered comparable T cell proliferation; however, co-cultured *Prkcb*^−/−^ B cells exhibited reduced proliferation compared to WT B cells ([Figures 2](#fig2){ref-type="fig"}E and 2F) despite having normal survival responses ([Figures 2](#fig2){ref-type="fig"}G and 2H). When *Prkcb*^−/−^ B cells received CD40L, anti-IgM, and IL-4 (potent stimuli that mimicked B-T cell co-culture), they proliferated as robustly as WT cells ([Figure 2](#fig2){ref-type="fig"}I), indicating that the impaired proliferation of co-cultured *Prkcb*^−/−^ B cells was likely a result of reduced T cell help. While *Prkcb*^−/−^ B cells induced the proliferation of OT-II T cells ([@bib24]), the impaired antigen polarization in *Prkcb*^−/−^ B cells correlated with a reduction in antigen presentation to T cells. To further affirm this, we analyzed the effects of nocodazole or Gö6976 (classical PKC inhibitor) on WT B cells. Treatment with either nocodazole or Gö8976 effectively blocked antigen polarization ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D) and Eα presentation ([Figures S2](#mmc1){ref-type="supplementary-material"}E and S2F) compared to control. These findings demonstrate that the altered polarization of antigen-containing compartments impaired antigen presentation in *Prkcb*^−/−^ B cells.

Antigen polarization is necessary to coordinate synergistic BCR and toll-like receptor 9 (TLR9) signaling in B cells ([@bib8], [@bib12]). To test whether synergistic signaling was affected in *Prkcb*^−/−^ B cells, CTV-labeled WT, *Prkca*^−/−^, and *Prkcb*^−/−^ B cells were cultured with anti-IgM and CpG-coated microspheres (see [STAR Methods](#sec4){ref-type="sec"}) and IL-4. We observed robust proliferation in both WT and *Prkca*^−/−^ B cells after 3 days of stimulation, while *Prkcb*^−/−^ B cells failed to proliferate to the same extent ([Figure 2](#fig2){ref-type="fig"}J). This difference was ablated when we stimulated *Prkcb*^−/−^ B cells under conditions where antigen polarization is irrelevant, such as with unlinked CpG and anti-IgM (with IL-4) ([Figure 2](#fig2){ref-type="fig"}K; [@bib8]). This suggests that synergistic signaling in *Prkcb*^−/−^ B cells was attenuated due to the lack of antigen polarization. In line with this, *Prkcb*^−/−^ B cells exhibited impaired PI3K signaling when stimulated with microspheres, but not unlinked CpG and anti-IgM ([Figures S2](#mmc1){ref-type="supplementary-material"}G and S2H). Taken together, our data suggest that PKCβ is required for antigen polarization and presentation, which provides an explanation, at least in part, for the reduction in Tfh and GC B cells in *Prkcb*^−/−^ chimeras.

PKCβ Instructs Plasma Cell Differentiation in B Cells {#sec2.3}
-----------------------------------------------------

Although the role of PKCβ in antigen polarization likely contributes to the immunodeficiency in *Prkcb*^−/−^ chimeras, the abrogation of plasma cell differentiation in *Prkcb*^−/−^ chimeras made us wonder whether PKCβ plays other roles in B cell differentiation. To test this, we analyzed plasma cell differentiation of WT and *Prkcb*^−/−^ B cells cultured *in vitro* with CpG, anti-IgM, IL-4, and IL-5 using flow cytometry. We found that plasma cell differentiation was reduced by more than 60% in stimulated *Prkcb*^−/−^ B cells compared to those of the WT, while class-switch recombination (as measured by expression of IgG1) was unaffected ([Figure 3](#fig3){ref-type="fig"}A). We observed similar trends when *Prkcb*^−/−^ B cells were cultured in CD40L ([Figure 3](#fig3){ref-type="fig"}B), LPS ([Figure 3](#fig3){ref-type="fig"}C), or with 40LB cells ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B), suggesting that this was independent of specific exogenous signals. Furthermore, we found that more *Prkcb*^−/−^ cells underwent class switching compared to the WT in response to LPS and 40LB stimulation ([Figures 3](#fig3){ref-type="fig"}C, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B). Notably, these changes in differentiation did not correlate to cell proliferation ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D), suggesting that this might be a misstep in fate decision. Taken together, our data demonstrate that PKCβ plays an intrinsic and crucial part in promoting plasma cell differentiation in B cells.Figure 3*Prkcb*^−/−^ B Cells Fail to Commit to Plasma Cell Differentiation(A--C) Representative plots and the corresponding quantifications of plasma cells and IgG1^+^ cells of WT and *Prkcb*^−/−^ B cells cultured in the presence of (A) CpG and anti-IgM, (B) CD40L, and (C) LPS (all in the presence of IL-4 and IL-5) for 4 days. Data are representative of at least 2 independent experiments with 2 mice in each group.(D) Expressions of PAX5 and IRF4 in primary WT and *Prkcb*^−/−^ B cells cultured in LPS, IL-4, and IL-5 for 4 days.(E) The size of IRF4^hi^ cells (gated) was quantified. Data are of at least 2 independent experiments with 2 mice in each group.(F and G) MA plot of genes that are differentially expressed (red) with p-adj \< 0.05 in activated WT cells (F) or in activated *Prkcb*^−/−^ cells (G) compared to resting WT cells.Error bars represent SEM. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

The initiation of the plasma cell differentiation requires the dual-regulation of transcription factors, PAX5 and IRF4 ([@bib33]). To understand how PKCβ regulates plasma cell development, we analyzed IRF4 and PAX5 expression in LPS-stimulated (with IL-4 and IL-5) WT and *Prkcb*^−/−^ B cells by flow cytometry ([Figures 3](#fig3){ref-type="fig"}D and 3E). We found that PAX5 and IRF4 expression increased in WT B cells on day 1 and 2 of the assay. On day 3, IRF4^hi^ cells downregulated PAX5 and adopted the typical plasma cell (IRF4^hi^PAX5^lo^) signature, with a doubling of this population detected by day 4 ([Figures 3](#fig3){ref-type="fig"}D and 3E). We discerned few differences in IRF4 and PAX5 expression in activated *Prkcb*^−/−^ B cells in the first 2 days of the assay; however, on day 3 and 4, despite maintaining an intermediate IRF4 expression, *Prkcb*^−/−^ B cells did not acquire the IRF4^hi^PAX5^lo^ signature ([Figures 3](#fig3){ref-type="fig"}D and 3E). Similar trends were observed using other combinations of stimuli ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Thus, these results reveal that *Prkcb*^−/−^ B cells fail to surpass the IRF4 expression threshold that is required for plasma cell differentiation ([@bib19], [@bib39]).

To elaborate on these findings, we performed genome-wide RNA sequencing (RNA-seq) on RNA extracted from WT and *Prkcb*^−/−^ cells cultured with LPS, IL-4, and IL-5 for 2 days (see [STAR Methods](#sec4){ref-type="sec"}) ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C; [Table S1](#mmc2){ref-type="supplementary-material"}). Consistent with the initiation of plasma cell differentiation ([@bib33]), we observed upregulation (UP, log~2~ fold change \> 0) of *Prdm1* and *Irf4* and downregulation (DN, log~2~ fold change \< 0) of *Bach2*, *Pax5*, and *Bcl6* in activated WT B cells compared to control cells (IL-4 stimulated) ([Figures 3](#fig3){ref-type="fig"}F and [S4](#mmc1){ref-type="supplementary-material"}A). When we compared activated *Prkcb*^−/−^ B cells with activated WT B cells ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C), we found that in contrast to WT cells, *Prkcb*^−/−^ cells exhibited decreased *Prdm1*, *Irf4*, and *Ighm* (μ chain) expression ([Figure 3](#fig3){ref-type="fig"}G) and increased *Bcl6* and *Pax5* expression ([Figure 3](#fig3){ref-type="fig"}G). In line with unimpaired class switch recombination ([Figures 3](#fig3){ref-type="fig"}A--3C, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B), *Aicda*, *Bach2*, and *Ighg1* (γ1 chain) expression were normal in *Prkcb*^−/−^ cells ([Figure 3](#fig3){ref-type="fig"}G; [@bib30], [@bib31]). Taken together, our data suggest that PKCβ promotes the transcriptomic program necessary for plasma cell differentiation.

PKCβ Facilitates Metabolic Reprogramming and Mitochondrial Remodeling in Activated B Cells {#sec2.4}
------------------------------------------------------------------------------------------

In order to understand how PKCβ instructs the plasma cell differentiation program, we applied gene set enrichment analysis (GSEA) to identify gross transcriptomic changes in activated *Prkcb*^−/−^ B cells. Within the 58 most downregulated (FDR ≤ 0.001) gene sets in *Prkcb*^−/−^ B cells, we noticed a predominant presence of gene sets relating to metabolism ([Figure 4](#fig4){ref-type="fig"}A). GSEA also identified gene sets relating to endoplasmic reticulum (ER) stress, protein modification, and anterograde membrane trafficking ([Figure S4](#mmc1){ref-type="supplementary-material"}D), which are expected events preceding plasma cell differentiation. Specifically, expression of multiple mitochondrial-related genes such as *Atad1*, *Gpt2*, and *Hacd3* increased by 1.5-fold (log~2~ fold change ≥ 0.5) after activation in WT cells but not in *Prkcb*^−/−^ B cells ([Figure 4](#fig4){ref-type="fig"}B). Furthermore, mirroring the GSEA results, the expression of several well-characterized nutrient carriers such as *Slc2a1* (GLUT1) and *Slc3a2* (CD98) were also reduced in activated *Prkcb*^−/−^ B cells ([Figure 4](#fig4){ref-type="fig"}C; [Table S1](#mmc2){ref-type="supplementary-material"}).Figure 4Activated *Prkcb*^−/−^ B Cells Exhibited Abnormal Metabolism and mROS Accumulation(A) GSEA plots of selected downregulated gene sets in *Prkcb*^−/−^ B cells.(B and C) Hierarchical clustered heatmaps showing expression of genes relating to (B) mitochondria and (C) solute carriers (*Slc*).(D) The normalized abundance of polar metabolites in culture supernatant as determined using gas chromatography-mass spectrometry (GC-MS) of WT and *Prkcb*^−/−^ B cells cultured in LPS, IL-4, and IL-5 for 2 days. Data are representative of 2 independent experiments of 2 mice in each group.(E) Percentage of ^13^C incorporation in activated WT and *Prkcb*^−/−^ B cells. Each dot represents one mouse (n = 5) and is the average of 3 technical replicates.(F--K) MFIs of MitoTracker Green (F), MitoTracker Red CMXRos (G), two-dimension representation (H and I), their ratios (J), and MFI of MitoSOX (K) in WT and *Prkcb*^−/−^ B cells cultured in LPS, IL-4, and IL-5 for 4 days. Data are representative of 3 independent experiments.Error bars represent SEM. See also [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

To examine the metabolic fitness of these cells, we compared the metabolomic fingerprints of cultured WT and *Prkcb*^−/−^ B cells (see [STAR Methods](#sec4){ref-type="sec"}). Notably, we observed reduced lactate abundance in the culture medium of *Prkcb*^−/−^ cells compared to WT cells ([Figure 4](#fig4){ref-type="fig"}D). Next, we compared mitochondrial oxygen consumption rate (OCR) and extracellular acidification rate (ECAR, which reflects lactate production) in resting and activated WT and *Prkcb*^−/−^ B cells using the extracellular flux (XF) system ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C). Accordingly, while *Prkcb*^−/−^ B cells showed normal respiration under resting conditions, in line with their metabolomics fingerprints, they exhibited reduced basal OCR and ECAR after 1 day of culture in LPS compared to WT cells ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C). Comparable OCRs and ECAR were observed by day 2 ([Figure S5](#mmc1){ref-type="supplementary-material"}C). These results were corroborated by ^13^C-glucose labeling metabolomics on activated WT and *Prkcb*^−/−^ B cells (see [STAR Methods](#sec4){ref-type="sec"}), wherein activated *Prkcb*^−/−^ B cells showed decreased labeling in lactate and alanine and increased labeling in late TCA metabolites, compared to WT cells ([Figure 4](#fig4){ref-type="fig"}E). Collectively, these results suggest that PKCβ promotes metabolic reprogramming during B cell activation.

Given that the observed transcriptomic and metabolic changes likely involve the mitochondria, we investigated the mitochondrial status in WT and *Prkcb*^−/−^ B cells before and after stimulation with LPS, IL-4, and IL-5. To this end, we combined MitoTracker green and MitoTracker red CMXROS staining to monitor fluctuations in mitochondrial mass and mitochondrial membrane potential (MMP) using flow cytometry ([Figures 4](#fig4){ref-type="fig"}F--4J). In WT B cells, LPS stimulation induced a rapid increase of mitochondrial mass and MMP, followed by a gradual decrease until the end of the assay on day 4 ([Figures 4](#fig4){ref-type="fig"}F and 4G). In contrast, while exhibiting normal mitochondrial mass and MMP at resting condition ([Figures 4](#fig4){ref-type="fig"}F and 4G), *Prkcb*^−/−^ B cells showed increased accumulation of mitochondrial mass and MMP compared to WT cells on day 1 and 2 after activation ([Figures 4](#fig4){ref-type="fig"}F and 4G). Furthermore, most of the *Prkcb*^−/−^ B cells failed to downregulate mitochondrial mass and MMP toward the end of the assay ([Figures 4](#fig4){ref-type="fig"}F--4I), in agreement with lack of plasma cell differentiation ([@bib15], [@bib26]). Likewise, the ratio between mitochondrial mass and MMP, which is indicative of mitochondrial quality, was reduced in activated *Prkcb*^−/−^ B cells ([Figure 4](#fig4){ref-type="fig"}J), indicating that mitochondrial homeostasis was altered in activated *Prkcb*^−/−^ B cells.

Mitochondria influence B cell fate via mROS generation ([@bib15]). Importantly, while we observed similar mROS accumulation in resting WT and *Prkcb*^−/−^ B cells, mROS accumulation was increased in *Prkcb*^−/−^ B cells immediately following activation (since day 1) compared to WT B cells ([Figure 4](#fig4){ref-type="fig"}K), temporally coinciding with the relative mitochondrial quality ([Figure 4](#fig4){ref-type="fig"}J). Unlike WT cells, the addition of ascorbic acid (ROS scavenger) did not increase plasma cell differentiation in *Prkcb*^−/−^ B cells ([Figures S5](#mmc1){ref-type="supplementary-material"}D--S5F; [@bib15]). Likewise, other mitochondrial-targeting antioxidants mitoquinone (MitoQ) and MitoTempo were ineffective in this context ([Figures S5](#mmc1){ref-type="supplementary-material"}G and S5H), indicating that although high mROS might have suppressed plasma cell differentiation in *Prkcb*^−/−^ B cells, low mROS alone was not sufficient to promote plasma cell differentiation in the absence of PKCβ. Overall, our findings demonstrate that PKCβ is essential to promote the fitness of mitochondrial and non-mitochondrial metabolism and regulate mitochondrial status and mROS homeostasis.

Mitochondrial Metabolism Couples Heme Biosynthesis to Drive Plasma Cell Differentiation {#sec2.5}
---------------------------------------------------------------------------------------

We next questioned how metabolism could affect plasma cell differentiation. Plasma cell differentiation is associated with increased biosynthesis of heme ([@bib50], [@bib15]), a porphyrin that is capable of inhibiting the activity of the transcription factor BACH2 ([@bib50]). Heme biosynthesis is a metabolite-demanding multistep process ([@bib1]) and is inhibited by high mROS ([@bib15]). Given that *Prkcb*^−/−^ B cells exhibited altered metabolism and mROS accumulation, we tested whether heme biosynthesis was impaired in *Prkcb*^−/−^ B cells. We found that the expression of *Hmox1* (hemoxygenase-1), typically induced by heme accumulation ([@bib50]), was among the DN genes found in activated *Prkcb*^−/−^ B cells ([Figure 5](#fig5){ref-type="fig"}A). We also observed that Protoporphyrin IX (PpIX, the final substrate of heme biosynthesis) accumulation was reduced in activated *Prkcb*^−/−^ B cells compared to WT cells ([Figure 5](#fig5){ref-type="fig"}B), indicating that metabolic changes in activated *Prkcb*^−/−^ B cells likely impaired heme biosynthesis and caused BACH2 hyperactivity.Figure 5Heme Addition Restores Effector Differentiation in *Prkcb*^−/−^ B Cells(A) MA plot showing downregulation of *Hmox1* in *Prkcb*^−/−^ B cells.(B) The relative accumulation of PpIX as quantified by flow cytometry in WT and *Prkcb*^−/−^ B cells cultured in LPS, IL-4, and IL-5.(C and D) mROS, PAX5, and IRF4 expression, CD138^+^ and IgG1^+^ cells as quantified by flow cytometry in WT and *Prkcb*^−/−^ B cells cultured in LPS, IL-4, and IL-5 for 4 days in the absence or presence of hemin (added on day 1). Data were analyzed using two-way ANOVA and are representative of at least 3 independent experiments.Error bars represent SEM.

Thus, to test whether heme supplementation would reverse fate decision in activated *Prkcb*^−/−^ B cells, we cultured WT and *Prkcb*^−/−^ B cells in LPS (with IL-4 and IL-5) in the presence or absence of exogenous hemin. On day 3 and 4, we analyzed mROS accumulation, IRF4 expression, plasma cell differentiation, and class switch recombination using flow cytometry ([Figures 5](#fig5){ref-type="fig"}C and 5D). Hemin addition reduced mROS accumulation and restored IRF4 expression ([Figure 5](#fig5){ref-type="fig"}C) and plasma cell differentiation ([Figure 5](#fig5){ref-type="fig"}D) in *Prkcb*^−/−^ B cells. These changes corresponded with a reduction in class switch recombination ([Figure 5](#fig5){ref-type="fig"}D), indicating a hemin-driven fate-decision switch ([@bib15], [@bib50]). Thus, our data suggest that PKCβ promotes an activation-induced metabolic program necessary for mROS homeostasis and heme biosynthesis that is critical for B cell fate determination.

PKCβ Controls Mitochondrial Status and mROS Accumulation Partly through mTORC1 {#sec2.6}
------------------------------------------------------------------------------

The mTORC1 signaling pathway is known to play an important role in cell growth, protein synthesis, and metabolism, as well as the regulation of mitochondrial biogenesis and function ([@bib22], [@bib29]). In order to examine whether the metabolic changes observed in *Prkcb*^−/−^ B cells involved alterations in mTORC1 signaling, we compared mTORC1 activity in WT and *Prkcb*^−/−^ cells before and after stimulation ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S6](#mmc1){ref-type="supplementary-material"}A). Using flow cytometry, we noticed that a portion of WT B cells initiated mTORC1 signaling on day 1, characterized by ribosomal protein S6 phosphorylation ([Figure 6](#fig6){ref-type="fig"}A), cell blasting ([Figure S6](#mmc1){ref-type="supplementary-material"}A), and surface expression of CD98 and CD71 ([Figure 6](#fig6){ref-type="fig"}B; [@bib51]). This mTORC1-active population doubled by day 2 ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S6](#mmc1){ref-type="supplementary-material"}A). In contrast, this population was reduced in activated *Prkcb*^−/−^ B cells ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S6](#mmc1){ref-type="supplementary-material"}A). Consistently, we observed decreased GLUT1 expression and altered expression of mTORC1-associated genes ([@bib9], [@bib22], [@bib51]) in activated *Prkcb*^−/−^ B cells ([Figures S6](#mmc1){ref-type="supplementary-material"}B and S6C). Importantly, while the upregulation of mTORC1 activity was a general feature of B cell activation ([Figure S6](#mmc1){ref-type="supplementary-material"}D), high mTORC1 signaling and CD98 expression specifically correlated with plasma cell differentiation ([Figure S6](#mmc1){ref-type="supplementary-material"}D). Taken together, these data provide evidence that PKCβ is important for mTORC1 signaling during early B cell activation.Figure 6*Prkcb*^−/−^ B Cells Had Impaired Early mTORC1 Signaling in Response to Activation(A and B) Phosphorylation of S6, CD98, and CD71 surface expression as analyzed by flow cytometry of WT and *Prkcb*^−/−^ B cells cultured in LPS, IL-4, and IL-5 for 2 days. Data are representative of at least 3 independent experiments.(C) mROS accumulation and plasma cell differentiation as quantified by flow cytometry in WT B cells cultured in LPS, IL-4, and IL-5 for 4 days. Rapamycin was added at various time points as specified.(D and E) S6 phosphorylation and CD98 and CD71 surface expression as analyzed using flow cytometry in WT B cells cultured in LPS, IL-4, and IL-5 for 2 days in the absence and presence of rapamycin (added on day 1).(F) Relative abundance of PpIX as quantified by flow cytometry of WT B cells cultured in LPS, IL-4, and IL-5 for 2 days in the absence and presence of rapamycin (added on day 1). Quantification represents data from 3 independent experiments.(G and H) mROS accumulation and plasma cell differentiation as quantified by flow cytometry of WT B cells cultured in LPS, IL-4, and IL-5 for 4 days in the presence of either rapamycin or rapamycin plus hemin (added on day 1). Data were analyzed using two-way ANOVA and are of 3 independent experiments.Error bars represent SEM. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Given that defects in mTORC1 signaling temporally coincides with alterations in metabolic reprogramming in *Prkcb*^−/−^ cells, we questioned whether disruption of mTORC1 signaling in WT B cells was sufficient to affect cell fate. Accordingly, we cultured WT B cells in LPS (with IL-4 and IL-5) for 4 days and inhibited mTORC1 function using rapamycin at different stages of B cell activation. We analyzed mROS accumulation and plasma cell differentiation on day 3 and day 4 using flow cytometry ([Figure 6](#fig6){ref-type="fig"}C). Notably, we found that inhibition of mTORC1 signaling on day 1 enhanced mROS accumulation and reduced plasma cell differentiation, which was in line with our observations in *Prkcb*^−/−^ B cells ([Figure 6](#fig6){ref-type="fig"}C). In contrast, we noticed that mTORC1 inhibition on either day 2 or 3 only mildly affected mROS accumulation and plasma cell differentiation ([Figure 6](#fig6){ref-type="fig"}C), suggesting that fate decision in B cells involves an early and somewhat transient wave of mTORC1 activity, corroborating recent findings ([@bib13]). Mechanistically, rapamycin treatment suppressed mTORC1 activity ([Figure 6](#fig6){ref-type="fig"}D), reduced cell size ([Figure S6](#mmc1){ref-type="supplementary-material"}E), and decreased CD98 and CD71 expression ([Figure 6](#fig6){ref-type="fig"}E) and PpIX accumulation ([Figure 6](#fig6){ref-type="fig"}F), which was reminiscent of *Prkcb*^−/−^ B cells. We thus questioned whether the lack of plasma cell differentiation rapamycin-treated WT cells was a consequence of reduced heme accumulation as in *Prkcb*^−/−^ cells. To address this, we measured plasma cell differentiation of WT B cells in the presence of rapamycin alone or of rapamycin and hemin ([Figures 6](#fig6){ref-type="fig"}G and 6H). We found that hemin supplementation partially increased plasma cell differentiation in rapamycin-treated cells without alleviating mTORC1 inhibition ([Figures 6](#fig6){ref-type="fig"}G, 6H, and [S6](#mmc1){ref-type="supplementary-material"}F), indicating that rapamycin inhibited plasma cell differentiation via heme homeostasis. Taken together, these results demonstrate that mTORC1 mediates plasma cell differentiation through mROS and heme homeostasis, providing a mechanism of the defects observed in *Prkcb*^−/−^ B cells.

Early mTORC1 Activity Promotes and Sustains Effector Fate Commitment in B Cells {#sec2.7}
-------------------------------------------------------------------------------

We were intrigued by the observation that hemin seemed to be more potent to *Prkcb*^−/−^ cells than rapamycin-treated WT cells. To better understand the relationship between heme homeostasis, mTORC1, and plasma cell differentiation, we studied the effect of hemin and rapamycin on BLIMP1 expression in WT B cells using the *Prdm1*^gfp^ system ([Figures 7](#fig7){ref-type="fig"}A--7C; [@bib16]). We noticed that hemin not only induced BLIMP1 expression ([@bib50]) but also increased S6 phosphorylation, cell blasting, and CD98 expression ([Figures 7](#fig7){ref-type="fig"}A--7C). Importantly, resting B cells did not respond to hemin ([Figure S6](#mmc1){ref-type="supplementary-material"}G), suggesting that while hemin promoted mTORC1 activity in activated B cells, it alone could not initiate mTORC1 signaling or plasma cell differentiation. On the other hand, rapamycin treatment not only inhibited mTORC1 activity, it also suppressed BLIMP1 expression, cell blasting, and CD98 expression ([Figures 7](#fig7){ref-type="fig"}A--7C). Collectively, our results strongly support a model of plasma cell differentiation that involves the crosstalk between mTORC1, BACH2, and BLIMP1 ([Figure 7](#fig7){ref-type="fig"}D).Figure 7Early mTORC1 Signaling Plays a Decisive Role in Effector Fate Decision in B Cells through Heme Metabolism(A--C) GFP expression, p-S6 (A), cell blasting (B), and CD98 and CD71 surface expression (C) as measured by flow cytometry of *Prdm1*^+/GFP^ B cells cultured in LPS, IL-4, and IL-5 for 2 days in the presence of rapamycin or hemin (added on day 1).(D) A proposed model relating mTORC1, BACH2, and BLIMP1.(E) p-S6, CD98, and CD71 expression as determined using flow cytometry of *Prkcb*^−/−^ B cells cultured in LPS, IL-4, and IL-5 for 2 days in the absence or presence of hemin (added on day 1). Data are representative of at least 2 independent experiments.(F) S6 phosphorylation, CD98, and CD71 surface expression as measured by flow cytometry of WT. Data are representative of 2 independent experiments.(G) Quantification of CD98 surface expression in *Cd19*^−/−^ B cells cultured in LPS, IL-4, and IL-5 for 2 days in the absence or presence of hemin (added on day 1). Data are representative of 2 independent experiments.(H) Expressions of PAX5, IRF4, CD138, and IgG1 and the corresponding quantifications as analyzed by flow cytometry of WT and *Cd19*^−/−^ B cells cultured in LPS, IL-4, and IL-5 for 3 days in the absence or presence of hemin (added on day 1). Data were analyzed using two-way ANOVA and are representative of 2 independent experiments.Error bars represent SEM.

To confirm that this was indeed the mechanism of rescue in *Prkcb*^−/−^ B cells, we stimulated *Prkcb*^−/−^ B cells *in vitro* with or without exogenous hemin and measured mTORC1 activity using flow cytometry ([Figure 7](#fig7){ref-type="fig"}E). Consistent with our hypothesis, we found that hemin addition increased S6 phosphorylation ([Figure 7](#fig7){ref-type="fig"}E) and CD98 expression ([Figure 7](#fig7){ref-type="fig"}E) in *Prkcb*^−/−^ B cells, suggesting that hemin restored plasma cell differentiation via the indirect activation of mTORC1 in the absence of PKCβ. Collectively, our data had revealed a vital role of PKCβ in B cell fate decision through the initiation of the mTORC1-BACH2-BLIMP1 program.

We wanted to determine whether deregulation of the mTORC1-BACH2-BLIMP1 program underlies the lack of plasma cell differentiation in other systems that are known to have PI3K or mTOR signaling deficiencies, such as CD19-deficient B cells ([@bib5], [@bib17]). We therefore cultured WT and *Cd19*^−/−^ B cells in LPS (with IL-4 and IL-5) in the presence or absence of exogenous hemin ([Figures 7](#fig7){ref-type="fig"}F--7H). We found that while WT B cells exhibited high mTORC1 signaling and robust CD98 expression 2 days after culture (as shown previously), activated *Cd19*^−/−^ B cells exhibited decreased mTORC1 activity and CD98 expression ([Figure 7](#fig7){ref-type="fig"}F), similar to *Prkcb*^−/−^ B cells. Hemin supplementation led to increased CD98 expression ([Figure 7](#fig7){ref-type="fig"}G), increased IRF4 expression, plasma cell differentiation, and decreased class switch recombination in *Cd19*^−/−^ B cells ([Figure 7](#fig7){ref-type="fig"}H). Taken together, our study proposes a model in which B cell metabolic reprogramming sustains the mTORC1-BACH2-BLIMP1 program and in turn drives effector differentiation in B cells.

Discussion {#sec3}
==========

We have uncovered the decisive role of PKCβ in B cell physiology: PKCβ mediates GC reaction and plasma cell development in response to T cell-dependent antigen challenge *in vivo*. While the immunodeficiency in *Prkcb*^−/−^ chimeras appears to be a consequence of multiple B cell-intrinsic impairments, we reason that the loss of antigen polarization and presentation specifically contribute to GC defects. Indeed, previous study had revealed such correlation in Cdc42-deficient B cells ([@bib6]). Impaired antigen presentation leads to reduced T cell help *in vivo*, which could delay GC formation and affinity maturation, as observed in both *Prkcb*^−/−^ and *Cdc42*^−/−^ B cells. We speculate that the defects in antigen positioning in *Prkcb*^−/−^ B cells likely affects antigen transfer to other secondary compartments such as TLR9^+^ vesicles ([@bib8]), which may explain the poor synergistic signaling and proliferative response in these cells when stimulated with microspheres *in vitro*. At this stage, how PKCβ control antigen positioning is unclear, although we suspect that PKCβ regulates organelle trafficking ([@bib42], [@bib18]).

In line with our *in vivo* observations, PKCβ-null mice fail to elicit antibody titer upon primary T cell-dependent immunization ([@bib23]). However, this appears to be less severe in the recall response ([@bib23]), implying that PKCβ deficiency may not affect memory generation during the primary challenge. Consistent with this, activated *Prkcb*^−/−^ cells were able to induce *Aicda*, *Bach2*, and *Ighg1* expression ([@bib19], [@bib30], [@bib31]), as well as undergoing class-switch recombination *in vitro*, which together support the notion that the development of class-switch compartment should be normal, if not enhanced in *Prkcb*^−/−^ chimeras. Future works should address whether BCR signaling is affected in PKCβ-deficient memory B cells.

We have shown that the lack of an mTORC1-mediated metabolic reprogramming in *Prkcb*^−/−^ B cells suppresses plasma cell differentiation. While mTORC1 inhibition is known to delay BACH2 downregulation and suppress plasma cells differentiation ([@bib20]), hyperactivity of mTORC1 enhances plasma cell differentiation ([@bib3]). Here, we have shown that early mTORC1 signaling instructs plasma cell differentiation through the crosstalk to BACH2, BLIMP1, and metabolic reprogramming. We demonstrate that mTORC1 inhibition not only suppresses respiration ([@bib9], [@bib29]) but also elevates mROS during B cell activation. We have revealed mROS accumulation and heme homeostasis as mechanistic connections between mTORC1 signaling and plasma cell differentiation. We speculate that heme accumulation constitutes an intrinsic part of metabolic reprogramming in WT B cells: PpIX accumulation increases concurrently with that of two mTORC1 targets, CD71 and *Hmox1* ([@bib9], [@bib51]). Heme exhibits anti-oxidant properties through hemoxygenase-dependent degradation ([@bib37]), which could also be relevant in this setting.

In terms of the mode of metabolic reprogramming, our results provided further evidence that B cells increase glycolytic flux upon activation ([@bib14], [@bib49]) and that PKCβ plays a role in regulating these changes ([@bib4]). Although respiratory rate might not directly affect cell fate in B cells ([@bib15]), metabolic status can heavily influence other downstream pathways through the supply of metabolites derived. In line with this, our metabolomics results indicate that activated *Prkcb*^−/−^ B cells exhibit a shift toward oxidative phosphorylation in compared to WT cells. While this may be beneficial to activated *Prkcb*^−/−^ B cells to supplement ATP production, it may divert metabolites from other biosynthetic processes necessary for cell growth and differentiation, such as succinyl-CoA that is required for heme biosynthesis. Additionally, mitochondrial status may influence the localization of heme biosynthetic enzymes. Thus, our results reflect that changes in mitochondria during B cell activation likely sustain the mTORC1-BACH2-BLIMP1 program through biosynthesis of heme.

How mTORC1 signaling is coupled to PKCβ is not addressed in this study. In mammalian cells, mTORC1 signaling is regulated by both PI3K-dependent and PI3K-independent mechanisms ([@bib22]). Notably, mTORC1 activity can be altered by nutrient availability, such as glucose or amino acids ([@bib11]). Nutrient availability also affects lysosome positioning, which also influence mTORC1 activity ([@bib21]). Reliance on each of these regulatory pathways is context specific ([@bib11]). Indeed, we observed a strong correlation between the activity of mTORC1 and expression of CD98 in WT B cells, suggesting that the regulation of mTORC1 may switch from PI3K dependent to PI3K independent at some point during B cell activation. While the use of fully supplemented media in our *in vitro* assays unlikely restricts nutrient availability, mTORC1 activity may be affected by altered surface expression of nutrient transporters such as GLUT1 or CD98 in *Prkcb*^−/−^ B cells ([@bib7], [@bib43]). It is also possible that mTORC1 defects in *Prkcb*^−/−^ B cells are a result of lysosome misplacement ([@bib21], [@bib42]). These would be in line with the role of PKCβ in vesicular trafficking described in this study and previously ([@bib18]). Moreover, the lack of *Prdm1* induction in *Prkcb*^−/−^ B cells can further suppress mTORC1 signaling through the loss of positive feedback ([@bib45]).

An increasing body of evidence suggests that mTORC1 signaling and metabolic reprogramming are key determinants for lymphocyte fate decisions. In activated T cells, mTORC1 signaling cooperates with Myc to determine effector functions ([@bib34], [@bib46]). We speculate that much of these also apply to B cells. Indeed, systems previously reported to exhibit defective PI3K or mTORC1 signaling, such as *Cdc42*^−/−^ and *Wipf*^−/−^, all display altered "effector" versus "memory" fate decisions ([@bib6], [@bib17]). With the inclusion of the *Prkcb*^−/−^ and *Cd19*^−/−^ model presented in this study, there is a convincing body of evidence that illustrates the decisiveness of mTORC1 signaling axis in steering fate decision in B cells ([@bib3], [@bib20]). Given that the dependence on mTORC1 seems to be transient, we speculate that early mTORC1 activity may initiate a crosstalk with BACH2, BLIMP1, and metabolic reprogramming, which later becomes a self-propagating program via positive feedback mechanisms to promote plasma cell differentiation. This would be in line with the behavior and function of mTORC1 activity in GC B cells ([@bib13]). Finally, we have identified the crucial role of PKCβ in promoting early mTORC1 signaling and regulating transcriptomic and metabolic reprogramming, which together instruct and maintain effector function in activated B cells.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-B220eBioscienceClone: \[RA3-6B2\]Anti-CD138BIoLegendClone: \[281.2\]Anti-CD16/32eBioscienceCAT: 14-0161-86Anti-CD19eBioscienceClone: \[eBio-1D3\]Anti-CD4BIoLegendClone: \[GK1.5\]Anti-CD44eBioscienceClone: \[IM7\]Anti-CD71BD BiosciencesClone: \[C2\]Anti-CD95BD BiosciencesClone: \[Jo2\]Anti-CD98BioLegendClone: \[RL388\]Anti-CXCR5BD BiosciencesClone: \[2G8\]Anti-ErkCell Signaling Techclone: \[137F5\]Anti-GL7BD BiosciencesClone: \[GL7\]Anti-GLUT1AbcamClone: \[SPM498\]Anti-IgDBD BiosciencesClone: \[11-26c.2a\]Anti-IgG biotinylatedSouthern BiotechCAT: 1030-08Anti-IgG1BD BiosciencesClone: \[A85.1\]Anti-IgM biotinylatedSouthern BiotechCAT: 1020-08Anti-IRF4BioLegendClone: \[IRF4.3E\]Anti-kappaBD BiosciencesClone: \[187.1\]Anti-MHCII:EaeBioscienceClone: \[eBioY-Ae\]Anti-Mouse-IgG HRPJackson ImmunoResearchCAT: 115-035-003Anti-Mouse-IgG2bLife TechnologiesClone: \[RMG2b-1\]Anti-p-AktCell Signaling Techclone: \[D9E\]Anti-p-S6Cell Signaling TechClone: \[D57.2.2E\]Anti-p-S6K1Cell Signaling TechClone: \[108D2\]Anti-PAX5BioLegendClone: \[IH9\]Anti-PD1eBioscienceClone: \[J43\]Anti-Rabbit-IgGLife TechnologiesCAT: A-11008Anti-Rabbit-IgG HRPJackson ImmunoResearchCAT: 111-035-144**Chemicals, Peptides, and Recombinant Proteins**CD40LR&D SystemsCAT: 1163-CLCFSEInvitrogenCAT: C34570Chloroform Optima grade (for HPLC, stabilized with Amylene)FISHER Chemicals UKN/ACpG (ODN 1826)SigmaN/ACellTrace violet (CTV)InvitrogenCAT: C34557Eα peptideInternal sourceN/AFCCPSigmaCAT: C2920Gö 6976CalbiochemCAT: 365250HeminSigmaCAT: [9039](mi:9039){#intref0010}Interleukin-4R&D Systems404-MLInterleukin-5R&D Systems405-MLL-ascorbic acidSigmaCAT: A92902LPSSigmaCAT: L3012MeOH Optima gradeFISHER Chemicals UKN/AMitoqunioneFOCUS BiomoleculesCAT: 10-1363MitoSOXLife TechnologiesCAT: M36008MitoTempoSigmaCAT: SML0737MitoTracker GreenLife TechnologiesCAT: M7514MitotTracker Red CMXRosCell Signaling TechCAT: 9082SMouse B cell isolation kitMiltenyiCAT: 130-090-862Mouse CD4 T cell isolation kitMiltenyiCAT: 130-104-454NocodazoleCalbiochemCAT: 487928Oligomycin ASigmaCAT: 75351RotenoneSigmaCAT: R8875Water Optima gradeFISHER Chemicals UKN/A**Deposited Data**RNA sequencing dataThis paperGEO: [GSE111702](ncbi-geo:GSE111702){#intref0015}**Experimental Models: Organisms/Strains***Prkca*^−/−^Michael Leitges (University of Oslo)N/A*Prkcb*^−/−^Michael Leitges (University of Oslo)N/A*Prdm1*^+/GFP^Internal sourceN/A*Cd19*^−/−^Internal sourceN/A

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Facundo D. Batista (<Fbatista1@mgh.harvard.edu>).

Experimental Models {#sec4.3}
-------------------

### Animal breeding and generation {#sec4.3.1}

PKCβ-deficient and PKCα-deficient mice were kindly provided by Michael Leigtes, Oslo. All mice were bred and maintained at the animal facility of Cancer Research UK and The Francis Crick Institute. The Animal Ethics Committee of Cancer Research UK, The Francis Crick Institute and the UK Home Office approved all experiments.

### Immunization, infection, ELISA and ELISPOT {#sec4.3.2}

For immunization, mice were injected intra-peritoneally with 50 μg NP~23~-KLH (Biosearch Technology) in 4 mg Alum (ThermoScientific). Blood samples were taken from the lateral tail-vein on day 0, 3, 7, 13, 28 after immunization. For infection, 10^4^ PFU of Vaccinia Virus Western Reserve strain (vacv) was injected into isoflurane-anesthetized animals in the footpads. NP-specific antibody titers were detected by ELISA, using NP~23~-BSA, NP~3~-BSA, and biotinylated anti--mouse IgM and IgG (Southern Biotech). Titers were determined from the dilution curve in the linear range of absorbance. All non-commercial ELISA plates were developed with alkaline-phosphatase streptavidin (Sigma) and phosphorylated nitrophenyl-phosphate (Sigma). Absorbance at 405 nm was determined with a SPECTRAmax190 plate reader (Molecular Devices). NP-specific antibody-secreting cells and vacv-specific antibody-secreting cells were captured using activated ELISPOT plates coated with either NP~23~-BSA or vacv respectively. Detection was made using biotinylated anti--mouse IgM (Southern Biotech), IgG (Southern Biotech). All ELISPOT plates were developed with alkaline-phosphatase streptavidin (Sigma) and the BCiP®/NBT reaction (Sigma). Images were acquired using CTL 4.0 (ImmunoSpot®).

### Cell isolation, labeling and culture {#sec4.3.3}

Splenic naive B or CD4 T lymphocytes were purified using negative B cell or CD4 T cell isolation kits yielding enriched populations of ∼95%--98% (B cells) and ∼80% (T cells), respectively (Miltenyi Biotec). Purified B or T cells were labeled in PBS with 2 μM CTV (Invitrogen) or 1 μM CFSE (Invitrogen) for 5 minutes at 37°C with 5% CO~2~. Cells were maintained in complete B cell medium (RPMI 1640 supplemented with 10% FCS, 25 mM HEPES, Glutamax, penicillin and streptomycin (Invitrogen), and 1% β-mercaptoethanol (Sigma)). For iGC feeder (40LB) cells, cells were cultured in DMEM supplemented with 10% FCS and penicillin and streptomycin (Invitrogen). Initial selection for CD40L- and BAFF-expressing cells was performed using G418 and puromycin as described ([@bib32]).

Method Details {#sec4.4}
--------------

### Proliferation analysis {#sec4.4.1}

CFSE- or CTV--labeled cells at a concentration of 10^6^ cells per mL were stimulated in complete B cell medium supplemented with combinations of 1 μg/mL LPS (Sigma) or 0.05 μg/ml CD40L (R&D Systems), 5 μg/ml anti-IgM F(ab)~2~ fragment (Jackson ImmunoResearch), 1.5 ug/mL CpG (Sigma) 10 ng/ml of IL-4 (R&D Systems), or 10 ng/ml of IL-5 (R&D Systems). CFSE or CTV dilution was measured after 3 or 4 days by flow cytometry. Various agents were added as follow: L-ascorbic acid (200 μM) on day1, Mitoqunione of specified concentrations, MitoTempo of specified concentrations, hemin (60 μM) on day 1 and Rapamycin (50 nM) on the specified time points.

### Antigen internalization and presentation {#sec4.4.2}

For internalization assays, purified B cells were loaded with IgM-coated beads on ice for 60 minutes. Cells were then washed with complete medium to remove excess antigen, and then incubated for 30 minutes at 37°C. Cells were fixed at different time points with 4% formaldehyde. After fixation, beads remaining on the cell surface were detected with Alexa488 streptavidin (eBioscience). To detect antigen presentation, B cells loaded with Eα peptide and IgM-coated beads were incubated between 3 and 5 hours at 37°C, and then fixed in 4% formaldehyde. These cells were then stained with anti-MHCII:Eα antibody, followed by anti--mouse IgG2b antibody staining for detection by flow cytometry.

### Microspheres preparation {#sec4.4.3}

For proliferation assay, 0.11 μm (diameter) streptavidin-coated microspheres (Bangs Laboratories) were incubated with a saturating amount of biotinylated anti-IgM and biotinylated-CpG (Sigma) or OVA (EMD Millipore) for 1 hour at 37°C, and washed to removed unbound molecules. For presentation assays, 0.11 μm red microspheres (Bangs Laboratories) were incubated with a saturating amount of biotinylated anti-IgM (Southern Biotech) and Eα peptide or OVA (EMD Millipore) for 1 hour at 37°C. Limiting stimulatory conditions were obtained by increasing the amounts of OVA or Eα peptide for coating, whereas IgM amounts were kept constant. Efficient titration of the IgM signal was measured by flow cytometry. Beads coated with anti-IgM were used as negative control. Red microspheres (Bangs Laboratories) coated with biotinylated anti-IgM (Southern Biotech) were used for internalization assay.

### Eα Peptide {#sec4.4.4}

Biotin-GSGFAKFASFEAQGALANIAVDKA-COOH was produced by the Crick Peptide Chemistry facility.

### Flow cytometry {#sec4.4.5}

For analysis of splenocyte populations, single-cell suspensions were prepared from homogenized spleens. Erythrocytes were destroyed with Lysis Buffer (BD Biosciences). Cells were treated with the appropriate combination of the following antibodies: CD16/32 (Fc block), B220, CD19, CD44, PD1, IgG1, IgD, CD95, GL7, CXCR5, CD4, and CD138. For analysis of *in vitro* B cell cultures, after blocking Fc receptors using anti-CD16/32 antibodies, CTV-labeled cells were stained with the antibodies CD138, IgG1, CD98 and CD71. For intracellular detection of PAX5, IRF4, p-S6K1, p-S6 and GLUT1, after blocking Fc receptors using anti-CD16/32 antibodies, cells were fixed and permeablized with Cytofix/Cytoperm (BD Biosciences). Antibody against PAX5 and IRF4 diluted in 1x Perm/Wash (BD Biosciences) were used. Primary antibody against p-S6K1, p-S6, GLUT1 and secondary Alexa488 or Alexa555-conjugated Goat-anti-Rabbit IgG antibody (Life Technologies) was used for their detection. Mitochondrial status was measured using MitoTracker Green (20 nM), MitoTracker Red CMXRos (20 nM) and MitoSOX (5 μM). Cells were labeled for 30 minutes at 37°C. Cells were washed once with 2% FCS supplemented PBS and analyzed by flow cytometry. The relative mitochondrial quality was calculated by normalizing the intensity (MFI) of MitoTracker Red CMXRos to the intensity (MFI) of MitoTracker Green. Data were acquired on LSR Fortessa (BD) and analyzed with FlowJo (Tree Star).

### PpIX measurement {#sec4.4.6}

Cells were analyzed using flow cytometry. Excitation at 405nm and emission at 605/40 nm were used.

### Immunoblotting {#sec4.4.7}

Purified B cells were left at 37°C for 10 minutes in Imaging buffer (PBS, 0.5% FCS, 1 g/L [D]{.smallcaps}-Glucose, 2 mM MgCl2, and 0.5 mM CaCl~2~) to equilibrate before stimulation. They were then stimulated for various times with 5 μg/ml anti-IgM F(ab)~2~ fragment (Jackson ImmunoResearch) and 1.5 ug/mL CpG, 10 ng/ml of IL4, 10 ng/ml of IL-5, or coated microspheres (see previous section). For immunoblotting, stimulated cells were then lysed in lysis buffer (20 mM Tris-HCL, pH 8.0, 150 mM NaCl, 5 mM EDTA, Protease Inhibitor cocktail (Roche), 10 mM NaF, 1 mM Na~3~VO~4~, and 1% NP-40) for 30 minutes on ice, and samples were loaded into 12% PAGE gel (BIO-RAD) for electrophoresis. Proteins were detected with antibodies against p-Akt (Ser473), p-S6k1 (Thr389) and Erk using the secondary HRP-conjugated anti--rabbit or anti--mouse antibodies (see Key Resources Table). Blot densitometry analysis was performed using the ImageJ (National Institutes of Health) software.

### Optical microscopy {#sec4.4.8}

Spleens were embedded in OCT and frozen in cold isopentane and 10 μm-wide frozen sections were cut with a cryostat. Sections were dehydrated and fixed in 4% paraformaldehyde, blocked with PBS containing 1% BSA, and 10% goat serum (IF blocking buffer). To label plasma cell population architecture, sections were also permeablized with PBS 0.3% Triton for 3 minutes. Staining was performed in IF blocking buffer with a combination of the following antibodies: B220, anti-κ, and GL7. Confocal imaging was performed with a LSM 780 microscope (Carl Zeiss) with a plan apochromat 20 × , NA 0.8 objective for tissue sections or a plan apochromat 63 × , NA 1.40 objective for other applications. Images were analyzed with Imaris (Bitplane) or ImageJ software. For tissue sections, tiled images were acquired and assembled with the Zen software.

### RNA sequencing and bioinformatics analysis {#sec4.4.9}

RNA from B cells were extracted and purified with MagMAX™ RNA isolation kit (Life Technologies). Samples were processed with KAPA hyper prep and sequenced using the HiSeq 4000 system. Sequencing on biological triplicates (WT) and duplicates (*Prkcb*^−/−^) generated libraries ranging 40-70 million, 101 bp paired end reads. Read trimming and adaptor-removal were performed using Trim Galore! (version 0.4.2). The RSEM package (version 1.2.31), and Bowtie2 (version 2.2.9) were used to align reads to the mouse genome (Ensembl GRCm38 release 85) and to obtain gene level counts. For RSEM, all parameters were run as default except '--forward-prob' that was set to '0'. Differential expression analysis was carried out with DESeq2 package (version 1.14.1) within R version 3.3.2. Genes were considered to be differential expressed with p~adj~ ≤ 0.05. Gene set enrichment Analysis (GSEA) (version 2.2.3) was done for each pairwise comparison using gene lists ranked using the Wald statistic. Gene set pre-ranked analysis was carried out with respect of gene sets C2 canonical pathways and C5 biological processes. All parameters were kept as default except for enrichment statistic (classic) and min/max size, which were changed to 5 and 50000 respectively. Gene signatures with FDR q-value ≤ 0.05 were considered significant. Heatmap of differential expressed genes belonging to gene ontologies; mitochondrion (GO:0005739) were generated using the gplots CRAN package (version 3.0.1). Genes were clustered using an Eisen distance matrix and average linkage clustering.

### Metabolomics fingerprinting {#sec4.4.10}

Polar metabolites were extracted and analyzed by GC-MS as follows: 5 μL culture supernatant was removed from each sample and polar metabolites were phase-partitioned from apolar metabolites by addition of 350 μL chloroform/methanol/water (1:3:3 v/v/v, containing 1 nmol *scyllo*-inositol as internal standard). Centrifugation (13,000 rpm, 10 mins, 4°C) was used to separate phases. The polar phase dried in a rotary vacuum concentrator and washed twice with methanol. Metabolites were analyzed as previously described ([@bib25]). In brief, metabolites were derivatized by methoximation \[20 μl 20 mg/ml methoxyamine-HCl (Sigma, 226904) in pyridine (Sigma, 270970) at RT, overnight\], and subsequent incubation with 20 μl N,O-bis(trimetylsilyl)trifluoroacetamide (BSTFA) + 1% trimethylchlorosilane (TMCS) (Sigma, 33148) for ≥ 1 hr. Metabolite analysis was performed by GC-MS using an Agilent 7890B-5977A system. Splitless injection (injection temperature 270°C) onto a 30 m + 10 m × 0.25 mm DB-5MS+DG column (Agilent J&W) was used, with helium as the carrier gas, in electron impact ionization (EI) mode. The initial oven temperature was 70°C (2 min), followed by temperature gradients to 295°C at 12.5°C/min and then to 320°C 25°C/min (held for 3 mins). Metabolites were identified and quantified by comparison to the retention times, mass spectra, and responses of known amounts of authentic standards using MassHunter Workstation software (B.06.00 SP01, Agilent Technologies).

### Extracellular flux assay {#sec4.4.11}

Naive and activated B cells were resuspended in Seahorse medium supplemented with 11 mM glucose and 2 mM pyruvate with pH adjusted to 7.4. Cells were settled on 96-well assay plate (Seahorse Bioscience) coated with poly-lysine (Sigma). OCR was recorded with the XF96 Extracellular Flux analyzer. Oligomycin-sensitive OCR represents the difference in OCR before and after addition of 3 μM of Oligomycin A (Sigma). Other chemicals used: FCCP (5 μM) (Sigma); Rotenone (5 μM) (Sigma). Resting ECAR from the same assay was plotted.

### U-^13^C labeling assay {#sec4.4.12}

B cells cultured for 2 days were labeled with U-^13^C-glucose for 2 hours at 37°C. Metabolic activity was quenched rapidly with ethanol/dry ice slurry. Cells were lysed and metabolites were extracted as follows: 600 μL chloroform:methanol (3:1v/v) was added to each sample and vortexed briefly before pulse sonication (3 × 8 minutes) in a water-bath sonicator at 4°C for 1 hour. Samples were spun (13,200 rpm, 4°C, 10 minutes), supernatant transferred to a new tube and dried in a rotary vacuum concentrator. The remaining pellet was re-extracted with 600 μL methanol:water (3:1v/v) followed by pulse sonication for 8 minutes at 4°C. Samples were spun (as above), and the supernatant added to the first extract and dried. Extracts were suspended in 50 μL chloroform and 300 μL methanol:water (1:1) to partition polar and apolar metabolites. Centrifugation (13,000 rpm, 10 minutes, 4°C) was used to separate phases. 150 μL of the polar phase were inserted in a LC-MS vial insert and 50 μL of a mixture of methanol/water (1:1 v/v, containing 1.5 nmol ^13^C, ^15^N-Valine as internal standard) were added. Metabolite analysis was performed by LC-MS using a Q-Exactive Plus (Orbitrap) mass spectrometer from Thermo Fisher Scientific (Bremen, Germany) coupled with a Vanquish UHPLC system from Thermo Fisher Scientific (Bremen, Germany). The chromatographic separation was performed on a SeQuant® Zic®-pHILIC (Merck Millipore) column (5 μm particle size, polymeric, 150 × 4.6 mm). The injection volume was 10 μL, the oven temperature was maintained at 25°C, and the autosampler tray temperature was maintained at 4°C. Chromatographic separation was achieved using a gradient program at a constant flow rate of 300 μl/min over a total run time of 25 min. The elution gradient was programmed as decreasing percentage of B from 80% to 5% during 17 minutes, holding at 5% of B during 3 minutes and finally re-equilibrating the column at 80% of B during 4 minutes. Solvent A was 20 mM ammonium carbonate and 1.4 mL/L of a solution of ammonium hydroxide at 35% in water (pH 9) and solvent B was acetonitrile. Metabolites were identified and quantified by accurate mass and retention time and by comparison to the retention times, mass spectra, and responses of known amounts of authentic standards using TraceFinder 4.1 EFS software (Thermo Fisher Sientific). Label incorporation and abundance was estimated using TraceFinder 4.1 EFS software. The degree of labeling of individual metabolites was estimated as the percentage of the metabolite pool containing one or more ^13^C atoms after correction for natural abundance isotopes. Abundance was given relatively to the internal standard.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Sample sizes were chosen on the basis of published work in which similar phenotypical characterization and similar defects were reported. Cohort randomization or 'blinding' of investigators to sample identity was not done in this study. For all statistical comparisons unless specified, the data for each group were compared with Student's t test and P values were calculated. Normal distribution of samples was assumed on the basis of published studies with analyses similar to ours. Statistically significant differences are indicated on the figures as follows: ^∗^p \< 0.05, ^∗∗^p \< 0.005, ^∗∗∗^p \< 0.0005, ^∗∗∗∗^p \< 0.00005.
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